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Various muscular dystrophies are associated with the defective glycosylation of a-dystroglycan and are
known to result from mutations in genes encoding glycosyltransferases. Fukutin-related protein (FKRP) was
identiﬁed as a homolog of fukutin, the defective protein in Fukuyama-type congenital muscular dystrophy
(FCMD), that is thought to function as a glycosyltransferase. Mutations in FKRP have been linked to a variety
of phenotypes including Walker–Warburg syndrome (WWS), limb girdle muscular dystrophy (LGMD) 2I and
congenital muscular dystrophy 1C (MDC1C). Zebraﬁsh are a useful animal model to reveal the mechanism
of these diseases caused by mutations in FKRP gene. Downregulating FKRP expression in zebraﬁsh by two
different morpholinos resulted in embryos which had developmental defects similar to those observed in
human muscular dystrophies associated with mutations in FKRP. The FKRP morphants showed phenotypes
involving alterations in somitic structure and muscle ﬁber organization, as well as defects in developing eye
morphology. Additionally, they were found to have a reduction in a-dystroglycan glycosylation and a shor-
tened myoﬁber length. Moreover, co-injection of ﬁsh or human FKRP mRNA along with the morpholino
restored normal development, a-dystroglycan glycosylation and laminin binding activity of a-dystroglycan
in the morphants. Co-injection of the human FKRP mRNA containing causative mutations found in human
patients of WWS, MDC1C and LGMD2I could not restore their phenotypes signiﬁcantly. Interestingly, these
morphant ﬁsh having human FKRP mutations showed a wide phenotypic range similar to that seen in humans.
INTRODUCTION
Several muscular dystrophies have been associated with gly-
cosylation defects of dystroglycan. Dystroglycan is a central
component of the dystrophin–glycoprotein complex (DGC),
a large protein complex essential for maintaining the integrity
of the sarcolemma by connecting components of the extra-
cellular matrix (ECM) to the internal cytoskeleton of the
muscle ﬁber. No human diseases have been associated with
the dystroglycan gene mutations. However, dag1-null mice
showed embryonic lethality (1), suggesting that dystroglycan
function is critical for normal embryogenesis. Mature dystro-
glycan consists of two isoforms (a- and b- dystroglycan) gen-
erated by post-translational cleavage of a precursor protein (2).
Additionally, a-dystroglycan subunit is capable of binding to a
variety of laminin isoforms and the proteoglycan molecules
agrin, perlecan and neurexins (2–5).
Several forms of muscular dystrophy are associated with the
defective glycosylation of a-dystroglycan and are caused by
mutations in six genes encoding putative glycosyltransferases:
POMGnT1, POMT1, POMT2, Fukutin, fukutin-related protein
(FKRP) and LARGE (6–13). These diseases include severe
forms of congenital muscular dystrophy associated with struc-
tural brain defects and variable eye involvement such as
Fukuyama-type congenital muscular dystrophy (FCMD),
muscle–eye–brain (MEB) disease (14) and Walker–
Warburg syndrome (WWS) (15). Mutations in the glyco-
syltransferase genes also cause much milder muscular
dystrophies such as the limb girdle muscular dystrophies
(LGMD) types 2I and 2K (16). In some cases, a spectrum of
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of these putative glycosyltransferase genes (6,7). The pathol-
ogy of these disorders has been attributed to the failure of
the resulting hypoglycosylated dystroglycan to bind to com-
ponents of the ECM (17).
FKRP was identiﬁed as a homolog of fukutin, the defective
protein on FCMD (13,18). The primary protein sequence pre-
dicted from the gene sequence indicates homology to a class
of proteins that are thought to function as glycosyltransferases,
speciﬁcally mediating O-linked glycosylation. The role of
FKRP in the glycosylation of a-dystroglycan remains
unclear. FKRP has been proposed as a putative glycosyltrans-
ferase based on similar sequences to other glycosyltrans-
ferases; however, this activity has not been conﬁrmed (19).
Mutations in FKRP have been linked to variable phenotypes
including congenital muscular dystrophy, also referred to as
MDC1C, and LGMD2I that may or may not be accompanied
by dilated cardiomyopathy. The range of phenotypic severity
due to FKRP mutations is very large and is not usually
observed for other genes involved with muscular dystrophy
(18). Some reports of FKRP mutations include descriptions
of founder mutations in the European population (826C .
A, L276I) and the Tunisian population (1364C . A, A455D)
(18,20,21). Moreover, recent reports showed that some
mutations in FKRP gene caused WWS (953G . A, C318Y)
and MEB (919T . A, Y307N) (22,23).
Zebraﬁsh represent a good model to investigate genes
involved in muscle development and degeneration, and they
serve as a good model for muscular dystrophy (19,24–31).
The zebraﬁsh expresses orthologues of many DGC components
(32).Zebraﬁshhaveglycosyltransferases withstronghomology
to the human forms including FKRP (33). Using a morpholino
against FKRP, the resulting knocked down morphants showed
an abnormal formation of muscle and eye analogous to the
human diseases (34). These results demonstrate the possibility
of the animal model of dysfunction of this glycosyltransferase.
In the present study, we have knocked down FKRP
expression in the zebraﬁsh using two different morpholinos
and obtained the same phenotypes in the resulting morphants
as previously reported (34). FKRP morphant embryos show
defects in muscle organization, eye development and reduction
in a-dystroglycan glycosylation. In addition, co-injection of a
control FKRP mRNA or mutated FKRP mRNAs either cor-
rected pathology or mimicked human clinical conditions. Inter-
estingly, the developmental symptoms in the FKRP morphant
were restored by injection of control FKRP mRNA, not by
mutated human FKRP mRNAs. Moreover, injection of human
FKRP restored the reduction of a-dystroglycan glycosylation
and laminin binding to a-dystroglycan. Our data suggest that
theﬁshmodelofhumanFKRPmutationsisusefultoinvestigate
the pathogenesis associated with the FKRP gene and serves to
elucidate the role of FKRP in developmental processes associ-
ated with the glycosylation of a-dystroglycan.
RESULTS
FKRP morphant morphology
We began the study of the function of FKRP in zebraﬁsh
embryo development by using two anti-sense morpholino
oligonucleotides (MO) to disrupt the translation of FKRP
mRNA during development. MO1 and MO2 were targeted
to regions containing the 5’-untranslated region (MO2)
and the start codon of ﬁsh FKRP mRNA (MO1). The
binding regions of MO1 and MO2 were not overlapping.
At 1 dpf, FKRP morphant injected FKRP MO1 (6 ng) and
FKRP morphant injected FKRP MO2 (6 ng) had abnormal
formation of their heads and eyes (Supplementary Data
S1). Moreover, the organization of their muscles was abnor-
mal in both FKRP morphants compared with controls.
FKRP morphants displayed alterations in somite mor-
phology observed as curved somite boundaries that are dis-
tinct from the regular v-shaped pattern observed in control
MO injected embryos (Supplementary Data S1). At 1 dpf,
mildly affected morphant embryos were also found to
have curved tails and a slight curvature of the somite
boundaries like previously reported (34). At 1 dpf, the fre-
quency of observed abnormalities was correlated with injec-
tion of increasing amounts of both FKRP MO1 and 2
(Supplementary Data S2).
At 4 dpf, the frequency of observed developmental abnorm-
alities was also found to correlate in a dose-dependant fashion
with amounts of both FKRP MO1 and 2 injected (Supplemen-
tary Data S2). Injection of 6 ng of MO1 resulted in a mixture
of different ﬁsh phenotypes with 40% of injected ﬁsh exhi-
biting developmental abnormalities, 40% appearing normal
and 20% of them dead. Fish injected with 3 ng of MO2 also
had a mixture of different phenotypes with 40% of injected
ﬁsh exhibiting developmental abnormalities, 20% appearing
normal and 40% of them dead. Injection of control morpholi-
nos to both of MO1 and MO2 (mis-matched at 5 bases; see
Materials and Methods) resulted in few observed abnormal-
ities which were likely caused by the injection procedure (Sup-
plementary Data S2).
FKRP morphant embryos lacked locomotor activity and did
not respond to touch with the normal escape response
observed in control embryos. Overall, FKRP morphants
appeared to have a smaller eye size compared with controls
(arrows in Fig. 1G and I) and many had inﬂated precardia
(arrowheads in Fig. 1G and I). FKRP morphant embryos
were also found to have an irregular arrangement of muscle
ﬁbers compared with control embryos (arrows in Fig. 2G
and I). To better visualize the structure and organization of
muscle ﬁbers of the morphants, FKRP morphant and control
embryos at 4 dpf were analyzed by birefringence assays
(Figs 1 and 2). FKRP morphant embryos were found to have
markedly reduced normal patterns of birefringence compared
with control (Figs 1H and 1J and 2H and I). To conﬁrm the
knock down of the expression of ﬁsh FKRP with morpholino
injection, endogenous FKRP protein was analyzed with anti-
bodies against ﬁsh FKRP. In control MO1 and MO2, the
FKRP directed antibody recognized 60 kDa protein on
western blots, a size predicted by the ﬁsh FKRP sequence.
The analysis of morphant 1 and 2 extracts showed that the
expression of FKRP protein in morphants was substantially
decreased compared with those of control MO1- and
MO2-injected ﬁsh (Fig. 2K). Western blot results show that
the morpholinos used in these injections were effective in
knocking down the expression of FKRP during zebraﬁsh
development.
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To examine the expression of other muscle proteins, anti-
bodies against dystrophin, b-dystroglycan, a-dystroglycan
and myosin heavy chain (MHC, slow ﬁber) were used for
immunohistochemistry on the morphant embryos. Dystrophin
and b-dystroglycan expression at the myosepta appeared
normal and identical to control (Fig. 3I and J); however, the
immunostaining of these antibodies indicated that somite
boundaries were misshapen with a curved appearance and a
less distinct v-shaped structure as seen in controls with loca-
lized variation in reactivity to the antibodies along the
lengths of the boundaries (Fig. 3I and J).
To investigate the glycosylation of a-dystroglycan in FKRP
morphant embryos, embryos at 4 dpf were immunostained
with the antibody VIA4-1, which reacts speciﬁcally to
glycosylated isoforms of a-dystroglycan (35). At 4 days,
VIA4-1 staining was mainly observed in normal embryos at
the somite boundaries (Fig. 3C and G). VIA4-1 staining of
Figure 2. Body and muscle structures in FKRP morphant at 4 dpf. (A and B)
Wild-type ﬁsh. (C and D) Control MO1 injected ﬁsh. (E and F) Control MO2
injected ﬁsh. (G and H) FKRP MO1 injected ﬁsh. (I and J) FKRP MO2
injected ﬁsh. (A), (C), (E), (G) and (I) show bright ﬁeld pictures. (B), (D),
(F), (H) and (J) show results of birefringence assay. Arrows highlight the dis-
organization of myosepta in FKRP morphants. Bar: 100 mm. (K) Immunoblot
of protein extracts of 4 dpf wild-type ﬁsh and 4 dpf ﬁsh injected with FKRP
MO1, MO2, control MO (CMO) 1 and 2.
Figure 1. Head and body in FKRP morphant at 4 dpf. (A and B) wild-type ﬁsh.
(C and D) Control MO1 injected ﬁsh. (E and F) Control MO2 injected ﬁsh. (G
and H) FKRP MO1 injected ﬁsh. (I and J) FKRP MO2 injected ﬁsh. (A), (C),
(E), (G) and (I) show bright images. (B), (D), (F), (H) and (J) show results of
birefringence assay. Arrows show smaller eyes in affected ﬁsh. Arrowheads
show inﬂated heart in affected ﬁsh. Bar: 100 mm.
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VIA4-1 (Fig. 3K) compared with controls.
Staining with anti-MHC demonstrated that the length of the
myoﬁbers appeared signiﬁcantly shorter than the control and
the gap between myoﬁbers appeared wider compared with
control (Fig. 3L), direct measurements given below.
Co-injection of normal or mutant mRNAs recapitulates
human phenotypes
Human and ﬁsh FKRP mRNAs were co-injected with the mor-
pholinos to determine whether they could rescue the develop-
mental phenotypes. FKRP mRNA (100 pg) and 3 ng of FKRP
MO2 were co-injected into 1-cell- or 2-cell-stage eggs.
Co-injection of ﬁsh or human FKRP mRNA with MO was
effective in the reduction of the number of ﬁsh affected with
the developmental phenotype at 1 dpf (Supplementary Data
S2) and 4 dpf (Fig. 4A). The percentage of affected ﬁsh and
those which died was reduced compared with MO-injected
ﬁsh, which indicated a partial rescue of the developmental
phenotype by these mRNAs. However, co-injection of
human FKRP mRNA bearing mutations was not as effective
in the recovery of these developmental phenotypes
(Fig. 4A). The percentage of recovered affected ﬁsh was vari-
able among L276I-, C318Y- and A455D-mutated human
FKRP mRNA injected ﬁsh (Fig. 4A). L276I-mutated ﬁsh
showed generally better developmental rescue of the pheno-
types; however, C318Y- and A455D-mutated ﬁsh had a high
percentage of abnormal embryos similar to morphants with
morpholino alone (Fig. 4A). The expression of mutant
FKRP proteins bearing a c-myc-tag encoded from the injected
FKRP mRNAs was conﬁrmed by anti c-myc antibodies
(Fig. 4B).
To examine the recovery of normal development in muscle
structures and eyes found in FKRP morphants (Figs 1G and I
and 2G and I), we measured the results of normal and abnor-
mal development. For muscle somites, the average control dis-
tance between myosepta was 85.2 mm. In FKRP control MO,
the distance was similar with an average of 82.8 mm. FKRP
morphant embryos showed an average distance of 72.4 mm
between myosepta. The distance between myosepta in FKRP
morphant embryos was signiﬁcant compared with control
(P , 0.001) (Fig. 4C).
Moreover, the normal distance between myosepta could be
restored to normal by co-injection of ﬁsh or human FKRP
mRNA (P , 0.001) (Fig. 4C). However, co-injection with
human FKRP mRNA containing human mutant alleles was
not as effective in recovery of these myosepta distances.
In wild-type ﬁsh embryos, the average eye diameter was
324 mm and in FKRP control MO injected embryos a
similar average diameter of 317 mm was observed. FKRP
morphants showed an average diameter of 200 mm
(Fig. 4D). These measurements indicated that the size of
eyes was signiﬁcantly different (P , 0.01). When normal
human or ﬁsh FKRP mRNA was co-injected, the reduced
diameter of eye was returned to near control diameter
(co-injection of human FKRP: 286 mm, ﬁsh FKRP:
295 mm). However, with co-injection of human FKRP
mRNA with mutant alleles, this recovery to normal diameter
was not observed. Moreover, measurements showed that phe-
notypes (eye diameter and the length between myosepta) of
ﬁsh co-injected the mutated FKRP mRNA were different
between the L276I, C318Y and A455D human FKRP
Figure 3. Immunostaining of FKRP morphant with antibodies against different muscle protein components. (A–D) wild-type. (E and F) Control MO2. (I–L)
FKRP MO2. (A), (E) and (I) show the results of immunostaining with anti-dystrophin. (B), (F) and (J) show the results with the anti b-dystroglycan antibody.
(C), (G) and (K) show the results with anti a-dystroglycan. (D), (H) and (L) show with anti-MHC. Arrows indicate the disturbance of myosepta in the FKRP
morphant. Arrowheads show the gaps between myoﬁbers at myosepta. Bar: 100 mm.
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an intermediate phenotype comparing the length between
myosepta (78.2 mm versus control 82.8 mm) and eye diameter
(252 mm versus control 324 mm). However, injection of the
C318Y- and A455D-mutated mRNAs yielded a similar
result to ﬁsh completely knocked down for the expression of
FKRP (Fig. 4A). The eye diameter and the length between
myosepta, for C318Y mutant, was smaller compared with
the L276I- and A455D-mutated ﬁsh (C318Y mutant: the
length between myosepta ¼ 70 mm and eye diameter ¼
191 mm; A455D mutant: the length between myosepta ¼
76.4 mm and eye diameter ¼255 mm) (Fig. 4C and D).
Recovery of muscle organization and glycosylation of
a-dystroglycan
When normal human and/or ﬁsh FKRP mRNA was
co-injected, birefringence of the ﬁsh was restored to normal
compared with morphants alone and mutated FKRP human
mRNAs (Fig. 5C–E). The normal mRNA co-injected ﬁsh
had a regularity of myosepta similar to that found in wild-type
(Fig. 5C and D). Co-injected L276I mutant mRNAs results in
mutant ﬁsh having nearly normal birefringence in skeletal
muscle compared with other mutant ﬁsh embryos. The ﬁsh
co-injected with the C318Y mutant mRNA had decreased
Figure 4. Restoration of normal development of FKRP morphant with co-injection of human and ﬁsh FKRP mRNA. (A) Histogram of the percentage of dead,
affected ﬁsh of morphants and recovered ﬁsh. Blue bar shows normal %, yellow shows affected % and gray shows dead ﬁsh %. (B) Immunoblot analysis of 4 dpf
ﬁsh extract with anti c-myc for detection of transcripts from the injected mRNA. b-Actin is used as the internal control. (C) Analysis of the length between
myosepta. Error bars represent standard divisions. Single asterisk indicates Student’s t-test P , 0.05. Double asterisks indicate P , 0.01. Triple asterisks indicate
P , 0.001. (D) Analysis of the diameter of eye. Single asterisk indicates Student’s t-test P , 0.01 and double asterisks indicate P , 0.001.
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mRNA showed no recovery of normal birefringence (Fig. 5H).
When normal human FKRP mRNA was co-injected, the gly-
cosylation of a-dystroglycan was restored (Fig. 6C).
Co-injection of the L276I mutant mRNA lead to the boundary
at myosepta that was sharp compared with other mutants
(Fig. 6D). The other two mutant alleles, C318Y and A455D,
had weaker glycosylation signals compared with L276I
mutant and control ﬁsh and very similar to that seen with
the morpholino alone.
To investigate the laminin-binding ability of a-dystroglycan
from FKRP morphant embryos, we examined morphants
co-injected control FKRP mRNA and mutated FKRP
mRNA, and measured a-dystroglycan-binding ability using
the laminin overlay assay and immunoblot with anti
a-dystroglycan.
The binding of laminin to a-dystroglycan puriﬁed from
4 dpf ﬁsh tissue was found to be at a lower molecular
weight compared with those from mouse muscle tissue and
adult tissues (Fig. 6G, lane 1 and 2). The band was also
detected with anti-a-dystroglycan (VIA4-1). Alpha-
dystroglycan had a lower molecular weight compared with
those of adult ﬁsh that were previously observed in laminin
overlay binding (34). The laminin-binding of a-dystroglycan
from FKRP morphant embryos was found to be signiﬁcantly
reduced compared with control and control FKRP mRNA
injected FKRP morphant (Fig. 6G, lane 3 and 4). Alpha-
dystroglycan puriﬁed from FKRP morphants co-injected
with control FKRP mRNAs showed that the afﬁnity to
a-dystroglycan was recovered compared with FKRP mor-
phants (Fig. 6G, lane 5).
The binding ability of a-dystroglycan from FKRP morphant
co-injected L276I mutated FKRP RNA was found to be
similar to the control (Fig. 6G, lane 6); however, FKRP mor-
phants co-injected mutated FKRP (C318Y or A455D) showed
reduced binding ability compared with control (Fig. 6G, lane 7
and 8).
In FKRP morphant embryos, the distance between the myo-
septa was reduced and the gap between myoﬁbers was greater.
To examine the nature of the protein structure at the gap, myo-
ﬁbers in mutant ﬁsh were examined by immunostaining with
anti-MHC and anti-laminin. In control and human normal
FKRP mRNA co-injected ﬁsh, the myoﬁbers were adjacent
at myosepta (Fig. 7A and B). The gaps between myoﬁbers
that were found in FKRP morphants (Fig. 7C) were also
reduced with the injection of normal human FKRP mRNA
(Fig. 7B). The length of myoﬁbers was of similar size to
that seen in control (Fig. 7A). Using the L276I mutant
allele, the gap was reduced compared with FKRP morphants
alone and the other two mutant alleles, C318Y and A455D
(Fig. 7D). In C318Y and A455D mutant alleles, the gap was
still wide and myoﬁbers were disturbed (Fig. 7E and F)
similar to that seen with the FKRP morphant alone.
DISCUSSION
Knockdown of FKRP levels by morpholinos during zebraﬁsh
development results in a clear disorganization of their skeletal
muscle. Abnormalities were not only conﬁned to skeletal
muscle but also in neurological tissues including the eye and
there were clear heart abnormalities. It is known that
mutations in the FKRP gene are associated with a spectrum
of neuromuscular human diseases ranging from very mild
LGMD2I to severe MDC1C and the most severe types
called MEB and WWS with neurological and ocular abnorm-
alities (13,18,36). Similar to what is observed in patients with
human mutations, FKRP morphant embryos had reduction in
eye diameter and muscle abnormalities, similar to results
seen by others (34). These results suggest that FKRP mor-
phants have characteristics which parallel clinical ﬁndings in
human patients. In LGMD2I and MDC1C patients, clinical
ﬁndings in muscle and dilated cardiomyopathy have been
reported (37–40). The ﬁndings in these FKRP morphants
suggest that FKRP morphant ﬁsh may have the characteristics
similar to myopathy, neuropathy and cardiomyopathy system
involvement in human disease. Using this ﬁsh model, further
studies focused on brain, eyes and heart may be useful for
understanding the mechanism of diseases in these systems.
In skeletal muscle, FKRP morphant ﬁsh have disturbed gly-
cosylation of a-dystroglycan and abnormal muscle structure
including myoﬁber size and an apparent gap at the myosepta.
Previous reports have also showed the effects on the glycosy-
lation of a-dystroglycan and on binding to the ECM ligand
laminin (34). The linking between a-dystroglycan and ECM
proteins with sugar chain of a-dystroglycan is known to be
important for supporting stable muscle structures. These struc-
tures rely on the effective glycosylation of a-dystroglycan and
carbohydrate modiﬁcations and are either absent or reduced
Figure 5. Birefringence assay of various FKRP injected ﬁsh at 4 days. (A)
Wild-type ﬁsh. (B) Control MO2. (C) Normal FKRP mRNA co-injected
ﬁsh. (D) Human normal FKRP mRNA co-injected ﬁsh. (E) FKRP MO2
injected ﬁsh. (F) Human mutated FKRP mRNA (L276I) co-injected ﬁsh.
(G) Human mutated FKRP mRNA (C318Y) co-injected ﬁsh. (H) Human
mutated FKRP mRNA (A455D) co-injected ﬁsh. Bar: 100 mm.
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to its ligands (41). A muscle degenerative phenotype has
also been described in morpholino-directed dystroglycan
knockdown ﬁsh embryos in which there is a disruption
of the DGC resulting in abnormalities in muscle ﬁber
organization (42).
Figure 6. Glycosylation abnormalities of a-dystroglycan and recovery of glycosylation by co-injection of FKRP mRNA with MO2. (A–F) Immunostaining of
4 dpf ﬁsh co-injected FKRP mRNA with anti a-dystroglycan (VIA4-1). (A) Control MO2. (B) FKRP MO2 injected ﬁsh. (C) Human normal FKRP mRNA
co-injected ﬁsh. (D) Human mutated FKRP mRNA (L276I) co-injected ﬁsh. (E) Human mutated FKRP mRNA (C318Y) co-injected ﬁsh. (F) Human
mutated FKRP mRNA (A455D) co-injected ﬁsh. Bar: 100 mm. (G) laminin overlay assay and western blot with a- and b-dystroglycan antibody.
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normal in the skeletal muscle of FKRP morphant; however,
myosepta were irregular and there is a wide gap between myo-
ﬁbers when compared with the control. These ﬁndings indicate
that modiﬁcation of sugar chains on a-dystroglycan may play
a critical role in maintaining myosepta length and the spacing
between myosepta. The lack of sugar modiﬁcation likely
causes a disconnection between myoﬁbers, and the muscle
degeneration decreased upon birefringence.
Somewhat surprising was the observation that the human
FKRP protein functions to partially restore normal ﬁsh
muscle structure. In addition, human FKRP mRNA with
mutations causing muscular dystrophy in humans is less effec-
tive at restoring structure compared with normal human
FKRP. This suggests that FKRP functions in the glycosylation
of a-dystroglycan thus making this model particularly appro-
priate for studies on the group of human diseases caused by
FKRP mutations. This model could also be used to map
domains on the human and ﬁsh FKRP proteins which are
important for normal development and function.
Interestingly, the FKRP morphants co-injected with human
FKRP mutations have a wide phenotypic range. In the
LGMD2I model ﬁsh with L276I mutation, the phenotypes
were generally mild similar to human patients with this
mutation. In LGMD2I patient, the clinical ﬁndings in muscle
and heart are mild compared with CMD (18). The reduced
abnormalities and laminin binding ability of a-dystroglycan
in ﬁsh co-injected with the human L276I mutation are consist-
ent with human relatively mild clinical ﬁnding course.
The zebraﬁsh models exhibited phenotypes similar to the
severe CMD and WWS with C318Y and MDC1C with
A455D mutations. In MDC1C, the muscle clinical ﬁndings
are severe (13) and in WWS, the clinical ﬁndings include
neurological, heart and skeletal muscle (22) and analogous
to this. C318Y mutation had abnormalities in eye formation
similar to those seen in WWS human patients.
In conclusion, these ﬁsh models of the human disease may
be very useful for understanding the pathogenesis of diseases
caused by mutations in the FKRP gene. Further investigation
using these knockdown ﬁsh models and those ﬁsh bearing
human mutations which yield similar phenotypes to human
disease may give clues to the function of FKRP in the glyco-
sylation of a-dystroglycan and the maintaining of normal
muscle. These studies aid our understanding of the phenotypic
spectrum in human muscular dystrophies associated with
mutations in the FKRP gene and these ﬁsh models are very
useful in testing for therapeutic compounds for these muscular
dystrophies.
MATERIALS AND METHODS
Fish strains and maintenance
Thezebraﬁshwild-typestrain(AB) wasusedinthisstudy.Zeb-
raﬁshembryos werecollected andraised at28.58 8 8 8 8Caccording to
standard procedures (43) and staged in hours or days post-
fertilization (hpf or dpf) according to standard criteria (44).
Anti-sense MO injection
Anti-sense MO (Gene Tools LLC) targeted to interfere with
FKRP translation were designed using the 50 sequence around
the putative start of translation of the zebraﬁsh FKRP mRNA
(NCBI accession number NM_001042689). The morpholino
sequences were FKRP MO 1: 50-TGGCAAAAACTGATAC
GCATTATGG-30,F K R PM O2 :5 0-CTTGTGGTTTTATGGC
AGAAAGAGT-30. For control MO, we used two 5 mis-
sequence control morpholino, mis-Control MO1: 50-TGcC
AtAAACTcATACcCATTATGc-30, mis-Control MO2: 50-
CTTcTGcTTTTATGcCAcAAAcAGT-30 (ﬁve mismatched
nucleotides in lower case). Morpholinos were re-suspended in
1x Danieau solution [58 mM NaCl, 0.7 mM KCl, 0.4 mM
MgSO4, 0.6 mM Ca (NO3)2,5m M HEPES; pH 7.6] with 0.1%
phenol red as an injection indicator. Morpholinos were injected
into the yolk of one-cell- to two-cell-stage embryos. Embryos
were injected with 1.5–12 ng of morpholino depending on
experimental condition.
Cloning of zebraﬁsh and human FKRP
Zebraﬁsh total RNA was extracted from 1 dpf wild-type
embryos and puriﬁed with RNeasy micro kit (QIAGEN) and
total RNA (500 ng) was converted to cDNA using SuperScript
III ﬁrst-strand system for RT–PCR (Invitrogen) according to
the manufacturer’s protocol. Primers used to amplify the full-
length ﬁsh FKRP cDNA coding sequence were forward:
50-CCATAATGCGTATCAGTTTTTTGCCAGG-30,r e v e r s e :
50-TTCCCAAACAATGCACACAC-30. The PCR product of
the full-length FKRP cDNA was cloned into pGEM
easy-T-vector (Stratagene). The FKRP gene sequence was con-
ﬁrmed by sequence analysis and the cDNA then cloned into
pcDNA3.1/myc-His C (Invitrogen). PCR products of C-
terminal region that ampliﬁed sequences with forward primer:
50-ATGTTTCGGGACAGTTCGAG-30, reverse primer: 50-CG
AGCGGCCGCCGATCCAAATGTGCG-30, were inserted into
Figure 7. The gaps between myoﬁbers can be repaired by co-injection of
normal FKRP mRNA with MO2 but not all human mutant alleles.
Co-immunostaining of 4 dpf ﬁsh co-injected FKRP mRNA with anti MHC
(green) and anti laminin (red). (A) Control MO2. (B) Human normal FKRP
mRNA co-injected ﬁsh. (C) FKRP MO2 injected ﬁsh. (D) Human mutated
FKRP mRNA (L276I) co-injected ﬁsh. (E) Human mutated FKRP mRNA
(C318Y) co-injected ﬁsh. (F) Human mutated FKRP mRNA (A455D)
co-injected ﬁsh. Bar: 50 mm. In control and human control mRNA co-injected
ﬁsh, the myoﬁbers are adjacent at myosepta (arrows in A and B); however,
FKRP morphant has the gap between myosepta (arrowhead in C). In L276I
mutant ﬁsh, the gap is also narrowed (arrow in D). In C318Y and A455D
mutant ﬁsh, there still remain gaps similar to that found in FKRP morphant
ﬁsh (arrows in E and F).
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with Afe I & Not I (New England Biolads).
Human FKRP full-length cDNA was ampliﬁed by PCR
using a forward primer: 50- CCAGCTAGCCCCAGACTTC-30,
reverse primer: 50-CTTGGTCAGTTTCCCCCTTC-30 using
human normal skeletal muscle cDNA (Invitrogen) as a tem-
plate. The PCR product of the full-length human FKRP
cDNA was cloned into pGEM easy-T-vector (Stratagene).
The cDNA clones were sequenced to conﬁrm the ﬁdelity of
FKRP sequences. The cDNA was cloned into pcDNA3.1/
myc-His C. PCR product of C-terminal sequence ampliﬁed
by PCR with forward primer: 50-ACGCCCGCCTACCTC
TAC-30, reverse primer: 50-GGTGACCTCGAGCGCCGC
TTCCCGTCAGACTCAGC-30. The product was ligated into
FKRP cDNA in pcDNA3.1/myc-His C after digestion with
Xho I (New England Biolads).
All PCR products and cloned fragments were sequenced by
the Molecular Genetics Core Facility at Children’s Hospital
Boston using sequencing primers for FKRP sequence analysis
(Supplement Data S3).
Generation of expression constructs and in vitro
transcription of RNAs
Both human and ﬁsh FKRP, full-length FKRP mRNAs with
myc and His tag constructs were cloned into the pCS2þ
expression vector. With human FKRP constructs, two different
amino acid substitutions, the same as mutations found
MDC1C (1364C . A, A455D) and LGMD2I (826C . A,
L276I) patients, were incorporated into the expression vector
by site-directed mutagenesis kit (Stratagene). Primers for
mutagenesis were forward primer: 50-GGTGCCCCTGCCC
TTTGACGGCTTCGTGG-30, reverse primer: 50-CCACGAA
GCCGTCAAAGGGCAGGGGCACC-30: for the MDC1C
causative mutation (1364C . A, A455D). The forward
primer: 50-GGCATCCGCATAGTGAGCTGGGAAGGC-30,
reverse primer: 50-GCCTTCCCAGCTCACTAGGCGGAT
GCC-30: were used for the LGMD2I causative mutation
(826C . A, L276I). For insertion of WWS causative mutation
(953G . A, C318Y), the PCR product that ampliﬁed by
forward primer: 50-AGCGCTGGACGCCCCCCTGCTACCT
GCGCGCGCTGCGCG-30, reverse primer: 50-GGTCCACGT
CGTAGTCCCATGG-30 was inserted to human FKRP
cDNA construct in pCS2þ after digestion with AfeI and
NcoI. All clones were sequenced to conﬁrm that only the
intended mutations were incorporated into the constructs.
RNAs were synthesized from Asp718-digested pCS2þ plas-
mids using the sp6 mMessage mMachine kit (Ambion). The
RNAs were quantiﬁed by nano drop (Thermo scientiﬁc).
Phenol red (0.1%) was added to the RNA solution as a
tracer, and mRNAs (100 pg) were co-injected into 1-cell-stage
embryos with FKRP MO2. Following injection, embryos were
cultured in aquatic system at 28.58C.
Birefringence
Muscle birefringence was analyzed as previously described
(45) by placing anesthesized embryos on a glass polarizing
ﬁlter and covering the embryos with second polarizing ﬁlter.
The ﬁlters were then placed on an underlit dissecting scope
(Nicon, model SMZ1500) and the top polarizing ﬁlter
twisted until only the light refracting through the striated
muscle was visible. Since the degree of birefringence is
affected by the horizontal orientation of the ﬁsh, the ﬁsh
were gently oscillated back and forth to account for differ-
ences in positioning.
Zebraﬁsh FKRP antibody
An antibody directed against zebraﬁsh FKRP was produced by
Invitrogen custom service with synthesized peptides (C þ
NPQYPNPAKKRLDRSR; 517-530) as an antigen. The syn-
thesized peptides were used to absorb the antibodies as a
control for speciﬁcity of this antibody.
Immunohistochemistry
For immunohistochemical staining of whole ﬁsh, embryos
were stored in 100% methanol at 2208 8 8 8 8C after ﬁxation with
4% PFA overnight at 48 8 8 8 8C. Following rehydration with metha-
nol series (70–50% and PBS-T) and blocking with 2% casein,
1% BSA, 0.05% Tween 20 in PBS to reduce non-speciﬁc
binding, embryos were incubated separately with the follow-
ing antibodies: anti-dystrophin (1:100, Sigma), anti
b-dystroglycan (1:100, Novocastra), anti a-dystroglycan
(1:50, VIA4-1, Millipore), anti-MHC (1:50, F59, Hybridoma
bank) and anti-laminin (1:100, Sigma) at 48 8 8 8 8C overnight.
After washing several times, the samples were incubated
with secondary antibodies (1:500, either anti-mouse
AlexaFluor-488 or anti-rabbit AlexaFluor-568, Invitrogen).
The stained embryos were observed under the dissection
scope (Nikon, SMZ1500) with EXFO Fluorescence illumina-
tion system, X-Cite 120 (Photonic Solution Inc.), a Nikon
Eclipse E-1000 microscope, photographed using a Hamamatsu
digital camera, and images were acquired using Openlab soft-
ware version 3.1.5 (Improvision).
Measurement of eye diameter and distance between
myosepta
The diameter of the eye of 4 dpf embryos was measured under
a dissection scope (Nicon, SMZ1500) with Open lab software
(Improvision). The distance between myosepta was measured
with Open lab software (Improvision) under the dissection
scope (Nikon, SMZ1500) after immunostaining of 4 dpf
embryos with anti-b-dystroglycan. Measurements started
near the head for 10 subsequent myosepta.
Western blotting
Dechorinated and deyolked embryos were homogenized in
Tris-buffered saline (TBS) containing 2% Triton X-100 and
protease inhibitors. Following centrifugation at 14000g at
48 8 8 8 8C for 20 min, the concentration of protein in supernatants
was determined by Bradford method, using a protein assay
kit (Bio-rad). Proteins were separated by electrophoresis on
8–16% gradient Tris-glycine gels (Invitrogen) and transferred
onto PVDF membrane (Invitrogen). After blocking the mem-
brane in PBS containing 1% BSA, 2% casein, blotted proteins
were incubated with primary antibody, anti ﬁsh FKRP (1:100),
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After washing, the membranes were incubated with horse-
radish peroxidase secondary antibody (anti-rabbit or mouse
IgG, 1:15000, Invitrogen). Proteins were detected using a
western blotting detection kit (Millipore).
Laminin overlay assay
Laminin overlay assays were performed using mouse
Engelbreth-Holm-Swarm (EHS) laminin (Sigma) as previous
described (17). For the puriﬁcation of a dystroglycan, wheat
germ agglutinin (WGA)-agarose beads (Vector Labs) were
added to extracts containing equal amounts of total protein
and incubated overnight at 48 8 8 8 8C followed by elution from
WGA beads with SDS sample buffer. Tissue extracts were
made from adult zebraﬁsh (4-month-old ﬁsh) and adult
mouse muscle. Proteins were separated by electrophoresis on
4–12% gradient Tris-glycine gels (Invitrogen) and transferred
onto PVDF membrane (Invitrogen). PVDF membranes blotted
proteins were blocked in the binding buffer (10 mM triethano-
lamine, 140 mM NaCl, 1 mM MgCl2,1m M CaCl2, pH 7.6) con-
taining 5% non-fat dry milk followed by incubation with
laminin overnight. Membranes were incubated with rabbit
anti-laminin (1:5000, Sigma) followed by anti-rabbit
IgG-HRP (1:15000, Invitrogen). Proteins were detected
using a western blotting detection kit (Millipore). For detec-
tion of a- and b-dystroglycan, anti-a-dystroglycan (1:50,
VIA4-1, Millipore) and anti-b-dystroglycan (1:100, Novocas-
tra) were used.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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